AstraZeneca: Eli Lilly discovery pact won't raise competitive concerns
AstraZeneca has no competitive concerns about teaming with Eli Lilly to identify chronic kidney disease (CKD) targets.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs